Cyclosporine A and tacrolimus: In vitro investigations on the differential interactions with the cytochrome P450 system in rat and human liver

Experimental and Toxicologic Pathology

Volumn 54, Issue 5-6, 2003, Pages 467-473

  Lupp, Amelie ^a   Kuhn, Urs Dieter ^a   Herwig, Roland ^a   Karge, Elke ^a   Rost, Michael ^a   Scheele, Johannes ^a   Fleck, Christian ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Cyclosporine A; Cytochrome P450; Human; Rat; Species differences; Tacrolimus

Indexed keywords

7 ETHOXYCOUMARIN DEETHYLASE; CYCLOSPORIN A; CYTOCHROME P450 1A; CYTOCHROME P450 2A; CYTOCHROME P450 2B; CYTOCHROME P450 2C; CYTOCHROME P450 3A; EPITESTOSTERONE; ETHOXYRESORUFIN DEETHYLASE; OXYGENASE; PENTOXYRESORUFIN DEALKYLASE; TACROLIMUS; TESTOSTERONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; HYDROXYLATION; IN VITRO STUDY; LIVER; MALE; MOLECULAR INTERACTION; NONHUMAN; RAT;

ANIMALIA; STAPHYLOCOCCUS PHAGE 3A;

EID: 0037559365     PISSN: 09402993     EISSN: None     Source Type: Journal    
DOI: 10.1078/0940-2993-00281     Document Type: Article

References (45)

1. AITIO A: A simple and sensitive assay of 7-ethoxycoumarin deethylation. Ana l Biochem 1978; 85: 488-491.
2. AMACHER DE, SCHOMAKER SJ: Ethylmorphine N-demethylase activity as a marker for cytochrome P450 CYP3A activity in rat hepatic microsomes. Toxicol Lett 1998; 94: 115-125.
3. AUGUSTINE JA, ZEMAITIS MA: A comparison of the effects of cyclosporine (CsA) on hepatic microsomal drug metabolism in three different strains of rat. Gen Pharmacol 1989; 20: 137-141.
4. BRUNNER LJ, BENNETT WM, KOOP DR: Selective suppression of rat hepatic microsomal activity during chronic cyclosporine nephrotoxicity. J Pharmacol Exp Ther 1996; 277: 1710-1718.
5. BRUNNER LJ, BENNETT WM, KOOP DR: Cyclosporine suppresses rat hepatic cytochrome P450 in a time-dependent manner. Kidney Int 1998; 54: 216-223.
6. CHANG TKH, CRESPI CL, WAXMAN DJ: Spectrophotometric analysis of human CYP2E1-catalyzed p-nitrophenol hydroxylation. In: Methods in molecular biology, Vol. 107: Cytochrome P450 protocols (eds.: PHILLIPS IR, SHEPHARD EA), Humana Press, Totowa, New Jersey, 1997; pp. 147-152.
7. COMBALBERT J, FABRE I, FABRE G, et al.: Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P-450IIIA gene subfamily. Drug Metab Dispos 1989; 17: 197-207.
8. COPELAND KR, YATSCOFF RW, MC KENNA R-M: Activity of cyclosporine metabolites compared and characterized by mass spectroscopy and nuclear magnetic resonance. Clin Chem 1990; 32: 225-229.
9. CORREIA MA: Rat and human liver cytochrome P450: substrate and inhibitor specificities and functional markers. In: Cytochrome P450: structure, mechanism and biochemistry (ed.: ORTIZ DE MONTELLANO PR), Plenum Press, New York, London, 2nd edition, 1995; pp. 607-630.
10. DEGTYARENKO KN, FABAN P: Directory of P450-containing systems. http://www.icgeb.trieste.it/p450/; 2002.
11. DUELL E, FISCHER G, ASTRÖM A, VOORHEES J: Cyclosporine A metabolism by cytochrome P-450II occurs in microsomes from rat liver but not from normal epidermis or psoriatic lesions. J Invest Dermatol 1991; 96: 827-831.
12. EAGELING VA, TJIA JF, BACK DJ: Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br J Clin Pharmacol 1998; 45: 107-114.
13. ELLOUK-ACHARD S, MARTIN C, PHAM-HUY C, et al.: Implication of CYP 3A in the toxicity of cyclosporin G (CsG), cyclosporin A (CsA) and FK506 on rat hepatocytes in primary culture. Arch Toxicol 1997; 71: 437-442.
14. FABRE JM, PEDROSA R, BONARDET A, et al.: Metabolism of cyclosporine after orthotopic liver transplantation. Biochem Pharmacol 1993; 46: 1151-1157.
15. GONZALEZ FJ: Human cytochromes P450: problems and prospects. Trends Pharmacol Sci 1992; 9: 346-352.
16. GONZALEZ FJ, GELBOIN HV: Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab Rev 1994; 26: 165-183.
17. KLINGER W, MÜLLER D: The influence of age on the protein concentration in serum, liver and kidney of rats determined by various methods. Z Versuchstierk 1974; 16: 146-153.
18. KLINGER W, MÜLLER D: Ethylmorphine N-demethylation by liver homogenate of newborn and adult rats; enzyme kinetics and age course of Vmax and Km. Acta Biol Med Germ 1977; 36: 1149-1159.
19. KOLARS JC, STETSON PL, RUSH BD, et al.: Cyclosporine metabolism by P450 3A in rat enterocytes - another determinant of oral bioavailability? Transplantation 1992; 53: 596-602.
20. KRONBACH T, FISCHER V, MEYER UA: Cyclosporine metabolism in human liver: identification of a cytochrome CYP3 gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 1988; 43: 630-635.
21. LADONA MG, SPALDING DJ, EKMAN L, et al.: Human fetal and adult liver metabolism of ethylmorphine. Relation to immunodetected cytochrome P450 PCN and interactions with important fetal corticosteroids. Biochem Pharmacol 1989; 38: 3147-3155.
22. LAMPEN A, CHRISTIANS U, GUENGERICH FP, et al.: Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Drug Metab Dispos 1995; 23: 1315-1324.
23. LAMPEN A, CHRISTIANS U, BADER A, et al.: Drug interactions and interindividual variability of ciclosporin metabolism in the small intestine. Pharmacology 1996; 52: 159-168.
24. LEWIS DFV: Cytochromes P450: Structure, function and mechanism. Taylor & Francis, London, 1996.
25. LI G, TREIBER G, MEINSHAUSEN J, et al.: Is cyclosporin A an inhibitor of drug metabolism? Br J Clin Pharmacol 1990; 30: 71-77.
26. LUBET RA, MAYER RT, CAMERON JW, et al.: Dealkylation of pentoxyresorufin: a rapid and sensitive assay for measuring induction of cytochrome(s) P-450 by phenobarbital and other xenobiotics in rat. Arch Biochem Biophys 1985; 238: 43-48.
27. LUCEY MR, KOLARS JC, MERION RM, et al.: Cyclosporin toxicity at therapeutic blood levels and cytochrome P450 IIIA. Lancet 1990; 335: 11-15.
28. MAURER G, LOOSLI HR, SCHREIER E, KELLER B: Disposition of cyclosporin in several animal species and man. I. Structural elucidations of its metabolites. Drug Metab Dispos 1984; 12: 120-126.
29. MAURER G: Metabolism of cyclosporin. Transplant Proc 1985; 17: 19-25.
30. MAURER G, LEMAIRE M: Biotransformation and distribution in blood of cyclosporine and its metabolites. Transplant Proc 1986; 18: 25-34.
31. MÜLLER D: Influence of xenobiotics on drug metabolism and its sensitive detection. Exp Toxic Pathol 1990; 39: 187-194.
32. PEROTTI BY, PRUEKSARITANONT T, BENET LZ: HPLC assay for FK506 and two metabolites in isolated rat hepatocytes and rat liver microsomes. Pharm Res 1994a; 11: 844-847.
33. PEROTTI BY, OKUDAIRA N, PRUEKSARITANONT T, BENET LZ: FK506 metabolism in male and female rat liver microsomes. Drug Metab Dispos 1994b; 22: 85-89.
34. PICHARD L, FABRE I, FABRE G, et al.: Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos 1990; 18: 595-606.
35. PICHARD L, DOMERGUE J, FOURTANIER G, et al.: Metabolism of the new immunosuppressor cyclosporin G by human liver cytochromes P450. Biochem Pharmacol 1996; 51: 591-598.
36. POHL RJ, FOUTS JR: A rapid method for assaying the metabolism of 7-ethoxyresorufin by microsomal subcellular fractions. Anal Biochem 1980; 107: 150-155.
37. PRUEKSARITANONT T, CORREIA MA, RETTIE AE, et al.: Cyclosporine metabolism by rat liver microsomes. Evidence for involvement of enzyme(s) other than cytochrome P450 3A. Drug Metab Dispos 1993; 21: 730-737.
38. SANGALLI L, BORTOLOTTI A, JIRITANO L, BONATI M: Cyclosporine pharmacokinetics in rats and interspecies comparison in dogs, rabbits, rats, and humans. Drug Metab Dispos 1988; 16: 749-753.
39. SATTLER M, GUENGERICH FP, YUN CH, et al.: Cytochrome P450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 1992; 20: 753-761.
40. SHIRAGA T, MATSUDA H, NAGASE K, et al.: Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes. Biochem Pharmacol 1994; 47: 727-735.
41. STIFF DD, VENKATARAMANAN R, PRASAD TN: Metabolism of FK506 in differentially induced rat liver microsomes. Res Commun Cem Pathol Pharmacol 1992; 78: 121-124.
42. UEDA S, COOK M, ALAK AM: In-vitro metabolic studies of tacrolimus using precision-cut rat and human liver slices. J Pharm Biomed Anal 1996; 15: 349-357.
43. VICKERS AE, FISCHER V, CONNORS S, et al.: Cyclosporin A metabolism in human liver, kidney, and intestine slices. Comparison to rat and dog slices and human cell lines. Drug Metab Dispos 1992; 20: 802-809.
44. VINCENT SH, KARANAM BV, PAINTER SK, CHIU SH: In vitro metabolism of FK-506 in rat, rabbit, and human liver microsomes: identification of a major metabolite and of cytochrome P450 3A as the major enzymes responsible for its metabolization. Arch Biochem Biophys 1992; 294:454-460.
45. YOKOGAWA K, SHIMADA T, HIGASHI Y, et al.: Modulation of mdr1a and CYP3A gene expression in the intestine and liver as possible cause of changes in the cyclosporin A disposition kinetics by dexamethasone. Biochem Pharmacol 2002; 63: 777-783.